Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625534 | 0.82 | KMT2A (0.37) | KMT2ALMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL2622404 | 0.82 | KMT2A (0.37) | KMT2ALMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL329518 | 0.82 | KMT2A (0.38) | KMT2ALMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL2625532 | 0.82 | KMT2A (0.37) | KMT2ALMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL10340048 | 0.79 | ALDH1A1 (0.41) | KMT2ALMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL23766537 | 0.78 | KMT2A (0.35) | KMT2ALMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL12137138 | 0.78 | ALDH1A1 (0.37) | KMT2ALMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL23682596 | 0.78 | KMT2A (0.35) | KMT2ALMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL19791009 | 0.77 | CNR2 (0.33) | KMT2ALMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL19441508 | 0.77 | PKM (0.36) | KMT2ALMNASMN1; SMN2POLBUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2927228-B1 | Novel physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2016-09-07 | — | — | EP | disclosed |
| EP-2927228-A1 | Novel physiologically active substances | Eisai R&D Management Co., Ltd. (JP) | 2015-10-07 | — | — | EP | disclosed |
| EP-2266978-B1 | Novel physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-7893068-B2 | Macrolide compounds comprising 18,19-epoxytricosa-8,12,14-trien-11-olide derivatives; angiogenesis inhibitors; anticarcinogenic, antimetastasis, antiinflammatory, and antitumor agents; antihypoxic agents; endothelial growth factor suppressors; retinal neovascularization, diabetic retinopathy | MERCIAN CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| EP-2266978-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-7619100-B2 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7550503-B2 | Physiologically active substances | EISAI R& D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20080275059-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | KOTAKE YOSHIHIKO | 2008-11-06 | — | — | US | disclosed |
| US-20080255146-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20060241171-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20060009439-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2006-01-12 | — | — | US | disclosed |
| EP-1508570-A1 | NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241171-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | KMT2A 3994/4885LMNA 4726/4885SMN1; SMN2 4612/4885 |
| US-20060009439-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | KMT2A 3994/4885LMNA 4726/4885SMN1; SMN2 4612/4885 |
| US-20080275059-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | HIF1A, HIF1AN, VEGFA | KMT2A 3994/4885LMNA 4726/4885SMN1; SMN2 4612/4885 |
| US-20080255146-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | HIF1A, HIF1AN, VEGFA | KMT2A 3994/4885LMNA 4726/4885SMN1; SMN2 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.